BIOCRYST PHARMACEUTICALS, INC. (BCRX) Operating Margin
- Operating margin · 12 months: Value (m); Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | (m) | Operating income / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -313.16M USD | Operating Income (Loss) |
| Revenue | (m) | |
| Cost of products and services | 20.93M USD | Cost of Goods and Services Sold |
| Research and development | 197.76M USD | Research and Development Expense |
| Selling, general and administration | 337.32M USD | Selling, General and Administrative Expense |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-313.16M | (m) | $20.93M | $197.76M | $337.32M | (m) |
| 2026-03-31 | $-381.84M | (m) | $19.88M | $189.18M | $360.73M | (m) |
| 2025-12-31 | $340.99M | (m) | $19.07M | $166.13M | $348.65M | (m) |
| 2025-09-30 | $76.10M | (m) | $15.65M | $174.70M | $333.16M | (m) |
| 2025-06-30 | $54.20M | (m) | $16.67M | $171.18M | $315.24M | (m) |
| 2025-03-31 | $33.17M | (m) | $15.57M | $165.41M | $289.11M | (m) |
| 2024-12-31 | $-2.54M | (m) | $12.27M | $174.64M | $266.13M | (m) |
| 2024-09-30 | $-40.70M | (m) | $7.73M | $195.25M | $250.04M | (m) |
| 2024-06-30 | $-60.32M | (m) | $5.62M | $201.05M | $235.61M | (m) |
| 2024-03-31 | $-89.78M | (m) | $4.82M | $214.67M | $225.39M | (m) |
| 2023-12-31 | $-103.71M | (m) | $4.48M | $216.57M | $213.89M | (m) |
| 2023-09-30 | $-107.35M | (m) | $5.31M | $219.72M | $199.66M | (m) |
| 2023-06-30 | $-112.87M | (m) | $7.75M | $225.58M | $185.94M | (m) |
| 2023-03-31 | $-126.89M | (m) | $7.10M | $236.32M | $172.96M | (m) |
| 2022-12-31 | $-148.44M | (m) | $6.41M | $253.30M | $159.37M | (m) |
| 2022-09-30 | $-154.30M | (m) | $4.44M | $243.62M | $144.60M | (m) |
| 2022-06-30 | $-181.44M | (m) | $1.49M | $240.85M | $142.68M | (m) |
| 2022-03-31 | $-176.30M | (m) | $1.54M | $231.73M | $130.99M | (m) |
| 2021-12-31 | $-177.72M | (m) | $7.23M | $208.81M | $118.82M | (m) |
| 2021-09-30 | $-177.95M | (m) | $6.84M | $180.63M | $104.42M | (m) |
| 2021-06-30 | $-176.23M | (m) | $7.77M | $160.91M | $86.62M | (m) |
| 2021-03-31 | $-185.16M | (m) | $7.47M | $135.53M | $74.18M | (m) |
| 2020-12-31 | $-174.76M | (m) | $1.55M | $122.96M | $67.93M | (m) |
| 2020-09-30 | $-122.46M | (m) | $3.84M | $114.38M | $57.43M | (m) |
| 2020-06-30 | $-114.69M | (m) | $2.33M | $109.26M | $51.97M | (m) |
| 2020-03-31 | $-111.10M | (m) | (m) | $109.44M | $46.75M | (m) |
| 2019-12-31 | $-99.45M | (m) | $3.73M | $107.07M | $37.12M | (m) |
| 2019-09-30 | $-124.61M | (m) | (m) | $103.72M | $31.12M | (m) |
| 2019-06-30 | $-118.00M | (m) | (m) | $100.61M | $27.31M | (m) |
| 2019-03-31 | $-101.34M | (m) | (m) | $93.94M | $28.14M | (m) |
| 2018-12-31 | $-94.22M | (m) | (m) | $84.89M | $29.51M | (m) |
| 2018-09-30 | $-86.82M | (m) | (m) | $78.38M | $29.72M | (m) |
| 2018-06-30 | $-71.67M | (m) | (m) | $73.88M | $25.14M | (m) |
| 2018-03-31 | $-68.94M | (m) | (m) | $68.63M | $18.48M | (m) |
| 2017-12-31 | $-57.41M | $25.19M | (m) | $66.96M | $13.93M | -227.95% |
| 2017-09-30 | $-47.74M | $30.28M | (m) | $62.20M | $11.80M | -157.66% |
| 2017-06-30 | $-43.63M | $29.28M | (m) | $58.79M | $11.21M | -149.00% |
| 2017-03-31 | $-40.24M | $30.97M | (m) | $57.20M | $11.10M | -129.95% |
| 2016-12-31 | $-48.61M | $26.35M | (m) | $61.01M | $11.25M | -184.45% |
| 2016-09-30 | $-57.61M | $21.97M | (m) | $67.90M | $11.41M | -262.21% |
| 2016-06-30 | $-61.53M | $25.20M | (m) | $73.86M | $11.39M | -244.22% |
| 2016-03-31 | $-44.06M | $46.25M | (m) | $76.22M | $12.20M | -95.27% |
| 2015-12-31 | $-39.44M | $48.26M | (m) | $72.76M | $13.05M | -81.74% |
| 2015-09-30 | $-37.41M | $49.10M | (m) | $72.22M | (m) | -76.18% |
| 2015-06-30 | $-35.85M | $41.35M | (m) | $65.19M | (m) | -86.70% |
| 2015-03-31 | $-52.81M | $16.98M | (m) | $59.73M | (m) | -311.12% |
| 2014-12-31 | $-45.77M | $13.61M | (m) | $51.80M | (m) | -336.35% |
| 2014-09-30 | $-36.95M | $18.73M | (m) | $49.54M | (m) | -197.28% |
| 2014-06-30 | $-32.26M | $17.88M | (m) | $44.24M | (m) | -180.45% |
| 2014-03-31 | $-32.79M | $17.23M | (m) | $44.70M | (m) | -190.23% |
| 2013-12-31 | $-30.72M | $17.33M | (m) | $42.73M | (m) | -177.24% |
| 2013-09-30 | $-35.08M | $10.87M | (m) | $38.21M | (m) | -322.85% |
| 2013-06-30 | $-36.17M | $14.24M | (m) | $42.30M | (m) | -254.05% |
| 2013-03-31 | $-34.20M | $17.63M | (m) | $43.35M | (m) | -194.05% |
| 2012-12-31 | $-33.89M | $26.29M | (m) | $51.46M | (m) | -128.89% |
| 2012-09-30 | $-34.23M | $27.42M | (m) | $54.23M | (m) | -124.87% |
| 2012-06-30 | $-39.02M | $26.90M | (m) | $57.26M | (m) | -145.04% |
| 2012-03-31 | $-43.09M | $26.43M | (m) | $58.94M | (m) | -163.04% |
| 2011-12-31 | $-49.59M | $19.64M | (m) | $56.90M | (m) | -252.44% |
| 2011-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-12-31 | $-34.36M | $62.38M | $86.00K | $83.90M | (m) | -55.08% |
| 2010-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-12-31 | $-13.74M | $74.59M | $4.54M | $73.66M | (m) | -18.42% |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |